OTEZLA
PeakNDAORALTABLET
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
OTEZLA by Bristol Myers Squibb is 4 (pde4) specific for cyclic adenosine monophosphate (camp). Approved for older, weighing at least 20 kg with active psoriatic arthritis, weighing at least 50 kg with active psoriatic arthritis and 3 more indications. First approved in 2014.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OTEZLA (apremilast) is an oral small-molecule phosphodiesterase 4 (PDE4) inhibitor approved in 2014 for psoriatic arthritis and moderate-to-severe plaque psoriasis in patients weighing at least 20 kg. It works by inhibiting PDE4, leading to increased intracellular cAMP levels, though the precise therapeutic mechanism remains incompletely understood.
$0.877BPart D
PeakOTEZLA is at peak commercial maturity with $877M in Part D spending (2023), suggesting a stable, well-established franchise with robust commercial infrastructure and maintenance-focused career opportunities.
Mechanism of Action
4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action is not well defined.
Indications (6)
Worked on OTEZLA at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.